 |
Video: What is a Stock Split?
|
 |
Capricor Therapeutics is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Co.'s main program, CAP-1002, is focused on the development and commercialization of a cell therapy comprised of cardiosphere-derived cells, which are an endogenous population of stromal cells isolated from donated cells of healthy human hearts for the treatment of DMD. According to our CAPR split history records, Capricor Therapeutics has had 2 splits. | |
 |

Capricor Therapeutics (CAPR) has 2 splits in our CAPR split history database. The first split for CAPR took place on November 12, 1997. This was a 1 for 10
reverse split, meaning for each 10
shares of CAPR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. CAPR's second split took place on June 05, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of CAPR owned pre-split, the shareholder now owned 1 share. For example, a 100 share position pre-split, became a 10 share position following the split.
When a company such as Capricor Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CAPR split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Capricor Therapeutics shares, starting with a $10,000 purchase of CAPR, presented on a split-history-adjusted basis factoring in the complete CAPR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/05/2013 |
|
End date: |
06/02/2023 |
|
Start price/share: |
$0.90 |
|
End price/share: |
$4.55 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
405.56% |
|
Average Annual Total Return: |
17.60% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$50,568.53 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
11/12/1997 | 1 for 10
| 06/05/2019 | 1 for 10 |
|
 |